INTRODUCTION
Atorvastatin (ATO) was a commonly drug used to lower blood cholesterol, but its use is currently limited because it caused harmful side effects to many organs, including the liver (Pal et al. 2015) . ATO is a statin that decreases production of low-density lipoprotein cholesterol by blocking action of HMG-CoA reductase enzyme in the liver at the rate-limiting step of cholesterol biosynthesis (Jacobson 2008) .
A primary cause of hepatic injury is oxidative stress via reactive oxygen species (ROS), which can directly or indirectly cause DNA or RNA damage, protein carbonylation, and lipid peroxidation. If not accounted for, the damage can lead to cell death and apoptosis (Lu et al. 2010 ). Therefore, antioxidants are important for protecting cells from oxidative stress. By accepting or donating electrons to ROS, antioxidants can convert ROS to less toxic molecules.
Nigella sativa is a natural antioxidant that has been used to treat a variety of diseases, such as asthma, diabetes, fever, and hypertension (Khader and Eckl 2014) . Thymoquinone (TQ) is a prominent constituent of the volatile oil of Nigella sativa seeds (Mabrouk, 2017) and has been investigated for its pharmacological effects, including antioxidant, antiinflammatory, antiapoptotic, antimicrobial, and anticancer activity. TQ has also been shown to offer hepatorenal protection against methotrexate-induced toxicity in rats (El-Sheikh et al. 2015) .
Despite the number of studies investigating the antioxidant, antiinflammatory properties of TQ against oxidative stress, there is no available information whether TQ can protect against ATO-induced hepatotoxicity. Thus, the objective of the current study was to investigate the mechanism of ATO-induced hepatotoxicity, whether posttreatment TQ could reverse the ATOinduced hepatic injury, and the mechanism of action of TQ as a hepatoprotective agent.
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MATERIALS AND METHODS
Materials
ATO, TQ, catalase activity (for rat homogenized liver tissue samples), and malondialdehyde (MDA) were purchased from Sigma-Aldrich Corp. (Saint Louis, MO, USA).
OxiSelect catalase activity (for rat serum samples) was purchased from Cell Biolabs, Inc. (San Diego, CA, USA). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) assay kits were purchased from DIALAB Diagnostics Co. (Wiener Neudorf, Austria). The reduced glutathione colorimetric assay kit was purchased from Biodiagnostic (Cairo, Egypt). The protein carbonyl colorimetric assay kit was purchased from Cayman Chemical (Ann Arbor, MI, USA).
Caspase 3 assay kit (colorimetric) was purchased from Abcam (Cambridge, United Kingdom).
Assays were analyzed using a spectrophotometer (DTN 402, DIALAB GmbH, Austria) at different wavelengths.
Experimental Design
Forty healthy, adult male Sprague Dawley rats (150-160 g) were purchased from the Animal House at the Faculty of Medicine at Cairo University in Cairo, Egypt. Rats were housed in a standard animal facility, which was maintained at a constant 23°C and 12:12-hour light-dark cycles. Rats had access to laboratory chow and water at all times. All persons involved in the study had completed animal care use and training. Experimental procedures, animal handling, sampling, and scarification followed the Guide for the Care and Use of Laboratory Animals, 8th edition (National Research Council 2011) and were approved by ethical committee of the Anatomy Department, Faculty of Medicine, Cairo University.
Before the start of the study, rats were left for 2 weeks to acclimatize. After that time, they were weighed and randomly divided into 4 groups of 10 rats. Group 1 (control group) D r a f t 6 received only water for 8 weeks through gavage once daily. Group 2 (TQ-treated group) received water for 8 weeks through gavage once daily and then 100 mg/kg/day body weight of TQ orally (Mansour et al. 2002) for 10 consecutive days (El-Sheikh et al. 2015) . Group 3 (ATO-treated group) received 30 mg/kg/day body weight of ATO for 8 weeks through gavage once daily (Pal et al. 2015) . Group 4 (combined ATO/TQ-treated group) received 30 mg/kg/day body weight of ATO for 8 weeks through gavage once daily (Pal et al. 2015) and then ATO administration was discontinued and replaced by 100 mg/kg/day body weight TQ orally once a day (Mansour et al. 2002) for 10 consecutive days (El-Sheikh et al. 2015) . Blood samples and livers from all groups were tested for liver enzymes, oxidative stress, and apoptosis markers and for histopathological and ultrastructural examination.
Sample Preparation
Three days after the last treatment of TQ, rats from all 4 groups were euthanized by cervical dislocation. Blood samples were collected from their caudal vena cava and centrifuged at 5000 rpm for 15 minutes. Serum was separated and stored at -80°C until use. Rat livers were dissected and weighed. Liver sections were placed in normal saline, processed in formalin (10%), and embedded in paraffin for morphological and cellular studies by histopathological examination. A series of 1 mm 3 pieces of rat livers were fixed in glutaraldehyde (3%) for 2 hours at room temperature, washed in phosphate buffer (0.1 M, pH 7.4) at 4°C, and post fixed with osmium tetroxide (2%) at 4°C for 2 hours. Samples were dehydrated, embedded in EponAraldite at 1:1 for 1 hour, and polymerized in an oven for 24 hours at 60°C. The remaining liver tissues were kept at -80°C after snap freezing in liquid nitrogen. Liver tissue homogenate was prepared by homogenizing the liver samples in potassium phosphate buffer (0.01 M, pH 7.4).
The liver homogenate was then centrifuged for 20 minutes at 3000 rpm. Aliquots (0.3 mL) of the D r a f t 7 supernatant were collected and kept at -80°C until use to avoid repeated thawing and refreezing.
Assessment of Total Body Weight and Liver/Total Weight Ratio
To assess the effects of TQ alone, ATO alone, and combined ATO and TQ on body weight, rat body weight was recorded before the study and after the study just before the rats were euthanized. Rat livers were weighed after dissection, and the liver weight/body weight ratio was calculated.
Assessment of Liver Biomarkers in Rat Serum
Hepatocellular function and hepatocellular toxicity were assessed using standard colorimetric ALT and AST assay kits and the modified International Federation of Clinical Chemistry UV kinetic method. Assays were analyzed using a wavelength of 340 nm.
Calibrations, quality controls, and assays were performed per manufacturer instructions using one calibration lot and one reagent lot for each parameter. Results were expressed in IU/L.
Assessment of ROS and Oxidative-Stress Markers in Rat Serum and Liver Homogenate
Calibrations, quality controls, and assays for ROS and oxidative stress markers were performed per manufacturer instructions using one calibration lot and one reagent lot for each parameter.
Reduced Glutathione Assay in Rat Serum and Liver Homogenate.-Reduced glutathione (GSH) is an important oxidative stress marker because it is an antioxidant that prevents the damage of cellular components by peroxides and free radicals of ROS (El-Sheikh et al. 2015) . GSH was measured in rat serum and homogenized liver tissue, using a reduced glutathione colorimetric assay kit. Assays were analyzed using a wavelength of 405 nm. Results were expressed in µmol/L in rat serum and µmol GSH/g in liver tissue homogenate. 
Catalase Assay in
Assessment of Apoptosis in Rat Liver Homogenate
Caspases (cysteine-requiring aspartate protease) are proteases that facilitate cell death.
Caspase 3 activity was measured using a caspase 3 colorimetric assay kit. Assays were analyzed using a wavelength of 405 nm. Calibrations, quality controls, and assays were performed per manufacturer instructions, using one calibration lot and one reagent lot for each parameter.
Results were expressed in arbitrary units.
Assessment of Liver Histology by Light Microscopy
Paraffin blocks of the liver tissues were sectioned at 5 µm thickness, stained with hematoxylin and eosin (H&E) and Masson's trichrome stain, and examined for histopathology When comparing treated groups (Groups 2-4), differences were found between the 3 groups for AST serum (Group 2 < Group 4 < Group 3), GSH homogenized liver (Group 3 < Group 4 < Group 2), and MDA homogenized liver (Group 2 < Group 4 < Group 3) ( Table 1) .
Group 2 was different from Groups 3 and 4 for GSH serum (Group 2 > Groups 3, 4), catalase homogenized liver (Group 2 > Groups 3, 4), and protein carbonylation homogenized liver (Group 2 < Groups 3, 4). Group 3 was different from Groups 2 and 4 for protein carbonylation serum (Group 3 > Groups 2, 4). Groups 2 and 3 were the only treated groups that had differences for total body weight (Group 3 < Group 2), ALT serum (Group 2 < Group 3), MDA serum (Group 2 < Group 3), and caspase 3 homogenized liver (Group 2 < Group 3). Groups 2 and 4
were the only treated groups that had differences for liver weight/total body weight ratio (Group 4 < Group 2). Groups 3 and 4 were the only treated groups that had differences for catalase serum (Group 3 < Group 4).
Group 1 H&E-stained sections had normal architecture of the hepatic lobules and were 
DISCUSSION
The liver is the main site that delivers ATO for the HMG-CoA reductase enzyme, which
is a core enzyme in cholesterol biosynthesis (Jacobson 2008; Pal et al. 2015; Sliskovic et al. 1992) . ATO is commonly well endured with minimal side effects, however, ATO-induced hepatocellular injury has been reported in 1.9%-5.5% of patients with drug-induced hepatocellular injury following dose escalation of ATO. Mortality due to ATO-induced hepatocellular injury has been reported in few patients, while most patients have improved after termination of ATO therapy. (Björnsson, 2016) . Further, research has shown that ATO-induced oxidative stress occurs through ROS (Qi et al. 2013 ). Examples of ROS include superoxide anion, hydrogen peroxide, and hydroxyl radical, which are chemically reactive molecules or free radicals that contain oxygen in their molecular structure (Ray et al. 2012 ). Thus, ATO-induced hepatotoxicity results from macromolecular and mitochondrial damage from increased intracellular production of ROS exceeding its natural antioxidant defense capacity (Halliwell and Gutteridge 2007 ).
In the current study, study groups were tested for liver enzymes, oxidative stress, and apoptosis markers and for histopathological and ultrastructural examination. No differences were found between Groups 1 and 2, which were the control and TQ-treated groups. However, statistically significant differences were found between Group 3, the ATO-treated group, and Groups 1 and 2 for all outcomes measures, except for catalase serum. There were also statistically significant differences between Group 3 and Group 4, the combined ATO/TQ-treated group.
In the current study, Group 3 had a lower total body weight and had a higher liver weight/total body weight ratio compared to Group 1. This result was explained in the histological analysis, which showed congestion in the central vein and sinusoids for Group 3 that were filled with RBCs, fluid exudate, and lymph.
The hepatotoxicity of Group 3 was evidenced by an increase in ALT serum and AST serum, which are membrane-leaking enzymes. There was also a simultaneous increase in protein carbonylation serum and MDA serum, which are markers of hepatic oxidative injury.
Glutathione is a vital antioxidant that prevents breakdown of the chief cellular components by ROS. Because of its oxidative breakdown of the lipid content of cell membranes, MDA is a marker for lipid peroxidation, and it acts as a marker of oxidative stress (Pal et al. 2015) .
Results of the current study suggested the mechanisms involved in the ATO-induced hepatotoxicity seen in Group 3 were related to oxidative stress. We found simultaneous decreases in GSH serum, GSH homogenized liver tissue, and catalase homogenized liver tissue in Group 3. Similar findings related to ATO-induced hepatotoxicity were reported by Pal et al. and an increase in MDA in response to ROS-induced injury by methotrexate in rat liver. In the current study, the reduction in the activity of GSH and catalase in Group 3 may be explained by ATO binding to glutathione reductase and catalase, respectively, and reducing the free enzymes available.
In the current study, the significant difference between Group 3 and Group1 for all compared outcome measures (except catalase serum) and the differences between Group 3, on one side, and Groups 2 and 4, for all compared outcome measures were supported by histological analysis of Group 3, which showed dilated and congested central veins and sinusoids.
Hepatocytes had degenerated cytoplasm, infiltrated by inflammatory cells, and disfigured nuclei. of Group 3, indicated the beginning of hepatic fibrosis. These differences were also supported by ultrastructural analysis of Group 3, which showed alteration of the normal cytoplasmic organelles and nuclei, suggesting degeneration in the hepatocytes.
Previous research has suggested that the normal dose of ATO for rats below which hepatic injury does not occur is 20 mg/kg/day (Ekstrand et al. 2015) . The current study was designed so that the 30 mg/kg/day body weight dose of ATO guaranteed hepatic injury (Pal et al. Similar findings for GSH, catalase, and MDA were reported by El-Sheikh et al. (2015) after the administration of TQ to treat ROS induced by methotrexate in rat liver. However, DalPizzol et al. (2001) reported that pretreatment with ROS scavengers decreased the elevated catalase and MDA activity. In other studies, Nagi and Mansour (2000) and Mansour et al. (2002) reported decreases in catalase and MDA after oral administration of TQ. Mansour et al. (2002) suggested the decrease in catalase and MDA were caused by less availability of free radicals, which are substrates for these enzymes, because of the free radical scavenging effect of TQ.
In the current study, the findings in Group 4 were supported by histological analysis, This conclusion was also supported by our ultrastructural analysis of Group 4, which showed restoration of the structure of the cytoplasmic organelles and nuclei. Taken together, these results suggested that posttreatment TQ alleviated the ATO-induced hepatotoxic effect in rat liver.
In the current study, there was a significant difference between Groups 3 and 1 for caspase 3 homogenized liver tissue. This result was confirmed during histological analysis of Group 3 because apoptotic cells were observed in the rat liver tissues. The mechanism of caspase 3 activation induced by ATO observed in the current study was explained by Gao et al. (2003) as an intracellular programed cell death mechanism that allows injured cells affected by oxidative stress to self-destroy through reduction in the membrane potential of the mitochondria. This causes the release of cytochrome C, apoptosome formation, and activation of the caspase cascade and other pro-apoptotic proteins in the cytosol (Gao et al. 2003) . Thus, caspases are widely considered as the executers of the apoptotic mechanism (Hengartner 2000 and Tarantino, et al., 2011) . Increased blood levels of cytochrome C, triglycerides, gamma-glutamyl transferase, and unconjugated bilirubin were detected in patients with NASH and FL (Tarantino, et al., 2011 ).
In the current study, Group 4 findings for caspase 3 homogenized liver tissue were greater than those of Group 1, suggesting posttreatment TQ prevented the creation of apoptotic bodies and protected the rat liver through this antioxidant property. This result was supported by previous studies where antiapoptotic properties of TQ in liver were shown to decrease expression of caspase 3 as a marker of apoptosis (El-Sheikh et al. 2015; Helal 2010 (Attoub et al. 2013 ).
To our knowledge, the current study is the first to demonstrate a posttreatment protective effect of TQ against high-dose, ATO in rat liver. Further, our results may be a valuable contribution to the existing literature, particularly since TQ is currently being investigated with a wide range of compounds because of its antioxidant, antiinflammatory (El-Sheikh et al. 2015; Mansour et al. 2002) , and antiapoptotic (Helal 2010) properties and its anticancer activities against certain tumors (Attoub et al. 2013 ).
The current study had some limitations. Although results of the current study proposed an effect of posttreatment TQ against high dose, ATO-induced hepatotoxicity, the study used a rat model, and the assumption that the same effects of TQ can be replicated with human patients cannot be made. Future studies should evaluate the effect of TQ to prevent high-dose, ATOinduced hepatotoxicity in a rat model and compare the efficiency of administering TQ before high-dose ATO and concomitantly to determine whether the structural histological damage caused by high-dose ATO can be reversed or not. Future studies should also investigate the posttreatment use of TQ to ameliorate high-dose, ATO-induced hepatotoxicity in humans. A study could also assess the effect of different doses of TQ to determine whether increasing the dosage increases the difference between Groups 3 and 4. 221x145mm (300 x 300 DPI)
